Select Page

Abstract Number: 772 – Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Presenter: Vania Hungria, MD, PhDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple MyelomaDate & Time: Monday, December 9, 2024 11:15 AM–11:30 AMLocation: Pacific Ballroom Salons 21-22 (Marriott Marquis...

Abstract Number: 770 – Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Presenter: Robert Z. Orlowski, MD, PhDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple MyelomaDate & Time: Monday, December 9, 2024 10:45 AM–11:00 AMLocation: Pacific Ballroom Salons 21-22 (Marriott...

Abstract Number: 769 – Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Presenter: Hartmut Goldschmidt, MDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple MyelomaDate & Time: Monday, December 9, 2024 10:30 AM–10:45 AMLocation: Pacific Ballroom Salons 21-22 (Marriott Marquis...